Vivanza Biosci.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE984E01035
  • NSEID:
  • BSEID: 530057
INR
2.07
0.09 (4.55%)
BSENSE

Apr 30

BSE+NSE Vol: 13.89 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Brawn Biotech
Beryl Drugs
Unjha Formul.
Vivanza Biosci.
Colinz Labs
Decipher Labs
Parmax Pharma
Genomic Valley
Ganga Pharma.
Fabino Enter
Shyama Computro.

Why is Vivanza Biosciences Ltd ?

1
Weak Long Term Fundamental Strength with a -4.85% CAGR growth in Operating Profits over the last 5 years
  • Low ability to service debt as the company has a high Debt to EBITDA ratio of -10.14 times
  • The company has been able to generate a Return on Equity (avg) of 9.70% signifying low profitability per unit of shareholders funds
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Vivanza Biosci. for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Vivanza Biosci.
-6.76%
-0.14
49.33%
Sensex
-4.15%
-0.31
13.42%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
53.38%
EBIT Growth (5y)
-4.85%
EBIT to Interest (avg)
0.43
Debt to EBITDA (avg)
0.68
Net Debt to Equity (avg)
2.07
Sales to Capital Employed (avg)
2.22
Tax Ratio
7.14%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
3.62%
ROE (avg)
9.70%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
35
Price to Book Value
1.80
EV to EBIT
-17.82
EV to EBITDA
-17.82
EV to Capital Employed
1.26
EV to Sales
0.16
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-0.64%
ROE (Latest)
-6.72%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company
NET SALES(9M)

At Rs 109.55 cr has Grown at 1,478.53%

PAT(9M)

Higher at Rs 0.85 Cr

0What is not working for the Company
Icon
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...

Here's what is working for Vivanza Biosci.

Net Sales - Latest six months
At Rs 100.61 cr has Grown at 2,135.78%
Year on Year (YoY)
MOJO Watch
Sales trend is very positive

Net Sales (Rs Cr)

Net Sales - Latest six months
Higher at Rs 100.61 cr
than preceding 12 month period ended Dec 2025 of Rs 13.92 cr
MOJO Watch
In the half year the company has already crossed sales of the previous twelve months

Net Sales (Rs Cr)

Profit After Tax (PAT) - Latest six months
Higher at Rs 0.76 cr
than preceding 12 month period ended Dec 2025 of Rs -0.85 cr
MOJO Watch
In the half year the company has already crossed PAT of the previous twelve months

PAT (Rs Cr)